HK Stock Market Move | DONGYUE GROUP (00189) rose over 8% in the afternoon as domestic refrigerant prices continued to rise, with core product prices reaching a nearly ten-year high for the same period.
Dongyue Group (00189) rose over 8% in the afternoon, and as of the time of writing, it has increased by 6.37%, reaching HKD 13.69, with a trading volume of HKD 342 million.
DONGYUE GROUP (00189) rose over 8% in the afternoon, and as of the time of writing, it increased by 6.37%, reaching HKD 13.69, with a trading volume of HKD 342 million.
On the news front, the prices of mainstream refrigerants such as R22, R32, R134a, and R410a continue to rise. According to market data from July 2026, domestic refrigerant prices are at historically high levels, exhibiting a trend of "high-level stability and continued increases in long-term contracts." Among them, the prices of core varieties like R32 and R134a have reached the highest levels in nearly a decade for the same period.
Kaiyuan Securities believes that during the first half of 2026, with the entire industry chain under pressure, the increase in long-term contract prices in the third quarter exceeded market expectations, and the industry logic of "price leads volume" remains solid. In the second half of the year, there is a high probability of global restocking of refrigerants, which could lead to better market performance. The firm believes that the scarce business model of refrigerants will transcend cycles, breakthroughs in high-end materials will verify growth, and short-term stock price fluctuations do not alter the industry logic, urging active engagement in long-term investment opportunities.
Related Articles

Youcare Pharmaceutical Group (688658.SH) subsidiary YKYY033 injection has received FDA clinical trial approval.

Guotai Haitong (02611) cancelled approximately 47.7862 million repurchased A-shares on August 12.

Shenwan Hongyuan Group: New ship prices continue to rise, and the performance verification cycle for shipping companies shows an upward trend.
Youcare Pharmaceutical Group (688658.SH) subsidiary YKYY033 injection has received FDA clinical trial approval.

Guotai Haitong (02611) cancelled approximately 47.7862 million repurchased A-shares on August 12.

Shenwan Hongyuan Group: New ship prices continue to rise, and the performance verification cycle for shipping companies shows an upward trend.

RECOMMEND





